Date of event
Wednesday, October 14, 2020 - 12:00 pm -
Wednesday, October 14, 2020 - 1:00 pm
Continuing Education Credits

Content Contributor

Cholestatic and Autoimmune Liver Diseases SIG


Aparna Goel, MD
Therese Bittermann, MD


John M. Vierling, MD, FACP, AGAF, FAASLD


Treatment failure. Incomplete response. Treatment intolerance. Management of autoimmune hepatitis can be extremely challenging when first-line therapy is inadequate. Join us for a discussion of alternative treatment options for autoimmune hepatitis and a review of their efficacy. Learn about updates to the treatment paradigm from the new 2019 guidelines!

Presenter Bios

Aparna Goel, MD

Dr. Aparna Goel is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University. She received her MD from Thomas Jefferson University and completed residency in Internal Medicine at the University of California San Francisco. She completed fellowships in Gastroenterology and Transplant Hepatology at Mount Sinai Medical Center in New York. She practices as a general and transplant hepatologist. She has a clinical and research interest in the management of patients with autoimmune liver diseases including autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis.

Photo of Aparna Goel, MD


Therese Bittermann, MD

Therese "Tess" Bittermann, MD is Assistant Professor of Medicine in the Division of Gastroenterology & Hepatology at the University of Pennsylvania (Penn). She also holds a secondary faculty appointment in the Department of Biostatistics, Epidemiology and Informatics and is Senior Fellow at the Leonard Davis of Healthcare Economics at Penn. On a national level, she serves as an elected member of the AASLD Clinical Research Committee and a member of the AASLD Cholestatic and Autoimmune Liver Diseases Special Interest Group. She will also be joining the editorial board of the journal Liver Transplantation and the medical advisory board of the Autoimmune Hepatitis Association this upcoming year.

Dr. Bittermann’s research interests center on the long-term consequences of chronic immunosuppression and practice heterogeneity in the management of liver transplant recipients and patients with autoimmune hepatitis (AIH). She is a current recipient of the 2020 Autoimmune Liver Diseases Pilot Research Award with which she plans to establish the epidemiology of AIH in the United States and evaluate the use of evidence-based management strategies in a national cohort of patients with AIH. She additionally receives funding from the National Institute of Diabetes and Digestive and Kidney Diseases through a K08 Career Development Award and is studying practice variability in immunosuppression management among liver transplant recipients and its impact on key clinical outcomes. Clinically, Dr. Bittermann is Transplant Hepatology-boarded and cares for patients with a wide range of liver diseases at a large, urban transplant center.

Photo of Therese Bittermann, MD

Moderator Bio

John M. Vierling MD, FACP, FAASLD, AGAF

John M. Vierling MD, FACP, FAASLD, AGAF is a tenured Professor of Medicine and Surgery and Chief of Hepatology and Director of Baylor Liver Health at the Baylor College of Medicine in Houston, Texas. He also serves as Director of Advanced Liver Therapies (a clinical research unit for adult liver diseases) and Program Director of the Hepatology and Liver Transplantation Fellowship. He graduated from Stanford University with a degree in Biology with Great Distinction and received his M.D. degree from Stanford University School of Medicine. Clinical interests include autoimmune and alloimmune liver diseases, liver transplantation, acute liver failure, viral hepatitis, non-alcoholic fatty liver disease, Wilson disease and drug-induced liver injury (DILI). His translational research interest is immunologic mechanisms of hepatobiliary injury. He has authored over 250 manuscripts, reviews and chapters. He is co-editor of Liver Immunology: Principles and Practice, now in its 3rd edition. Honors include Phi Beta Kappa, Alpha Omega Alpha, Best Doctors in America for 20 years, Top 1% physician rating by U.S. News and World Report, Who’s Who in America, Who’s Who in the World, Who’s Who in Science and Engineering and Who’s Who in Healthcare. He serves on the NIH NIDDK Liver Tissue and Cell Distribution System Coordinating Committee and on the DILI Network’s DSMB. He served previously as President of the American Association for the Study of Liver Diseases, Secretary-Treasurer of Digestive Disease Week® and Chairman of the National Board of Directors of the American Liver Foundation.

Photo of John M. Vierling MD, FACP, FAASLD, AGAF